ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods

• Type of Material: Article
• Authors: Sandra Weintraub, Northwestern University; Tatiana Karpouzian-Rogers, Northwestern University; John Devin Peipert, Northwestern University; Cindy Nowinski, Northwestern University; Jerry Slotkin, University of Delaware; Katy Wortman, Northwestern University; Emily Ho, Northwestern University; Emily Rogalski, Northwestern University; Cynthia Carlsson, University of Wisconsin; Bruno Giordani, University of Michigan; Felicia Goldstein, Emory University; John Lucas, Mayo Clinic; Jennifer J. Manly, Columbia University; Dorene Rentz, Harvard Medical School; David Salmon, University of California San Diego; Beth Snitz, University of Pittsburgh; Hiroko H. Dodge, Oregon Health and Science University; Michaela Riley, Northwestern University; Fatima Eldes, Northwestern University; Vitali Ustsinovich, Northwestern University; Richard Gershon, Northwestern University
• Language: English
• Date: 2021-11-17
• Publisher: WILEY
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2021 the Alzheimer's Association.
• Final Published Version (URL): http://dx.doi.org/10.1002/alz.12497
• Title of Journal or Parent Work: ALZHEIMERS & DEMENTIA
• Volume: 18
• Issue: 8
• Start Page: 1449
• End Page: 1460
• Grant/Funding Information: 1) Mayo Clinic Florida: NIA P50 AG016574 Mayo Clinic Alzheimer’s Disease Research Center; Florida Department of Health Ed & Ethel Moore Alzheimer’s Disease Research Program grant 8AZ08 Evaluating The Impact of a Dementia-Caring Community Model on African Americans with Alzheimer’s Disease and Their Care Partners; 2) Emory University: NIA 1P30AG066511 Goizueta Alzheimer’s Disease Research Center at Emory University; 3) University of California, San Diego: NIA P30AG062429 UCSD Alzheimer’s Disease Research Center; 4) NACC NIA U01 AG16976, National Alzheimer’s Coordinating Center; 5) Northwestern University: NIA P30 AG013854, Northwestern Alzheimer’s Disease Center; NIA R01AG045571, R56AG045571, and R01AG067781, Cognitive SuperAging studies; 6) University of Pittsburgh: NIA P50 AG005133, Alzheimer’s Disease Research Center, NIA P01 AG025204, Imaging Pathophysiology in Aging and Neurodegeneration, NIA R01 AG052446, Role of Midlife Cardiovascular Disease on Alzheimer’s Pathology and Cerebrovascular Reactivity in the Young-Old.; 7) Massachusetts General Hospital: NIA P30AG062421, Massachusetts ADRC; NCBI P01AG036694- Harvard Aging Brain Study; 8) University of Michigan: NIA P30 AG053760, Michigan Alzheimer’s Disease Research Center; NIA R01 AG054484, Community Based Approach to Early Detection of Transitions to Mild Cognitive Impairment and Alzheimer’s Disease in African Americans (ELECTRA); NIA R01 AG058724, Treating Mild Cognitive Impairment with High Definition Transcranial Direct Current Stimulation (STIM); NIH RF1 AG047866, Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals (REVEAL SCAN); Cure Alzheimer’s Fund, Deep Phenotyping of Older African Americans at Risk of Dementia; 9) Columbia University: Washington Heights-Inwood Columbia Aging Project (WHICAP), NIA PO1AG07232, R01AG037212, RF1AG054023, National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873; 10) University of Wisconsin: NIA P50 AG033514 and NIA P30 AG062715 Wisconsin Alzheimer’s Disease Research Center; 11) Oregon Health & Science University: Layton Aging and Alzheimer’s Disease Center, NIA P30 AG066518.
• Keywords: Science & Technology; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; RECOMMENDATIONS; Alzheimer's disease; neuropsychology; mild cognitive impairment; cognition; NIH Toolbox; Life Sciences & Biomedicine; RISK-FACTOR; DATA SET UDS; Neurosciences & Neurology; dementia; NATIONAL INSTITUTE; DECLINE; IMPAIRMENT; Clinical Neurology; DEMENTIA; NIH TOOLBOX
• Research Categories: Psychology, Cognitive; Biology, Neuroscience

Abstract

Introduction: Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods: Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion: Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study.